Beijing Refine Biology has announced the completion of a Series C financing round valued at over RMB 100 million. The proceeds will be used to drive commercial expansion, build new production capacity and accelerate R&D across the company's human and animal health platforms. Refine Bio positions itself as a leading supplier of naturally derived ingredients and solutions, leveraging both plant extraction and synthetic biology technologies.

The company operates three core product platforms: natural sweeteners, natural functional ingredients and pharmaceutical excipients. It has gained market traction, with its erythritol product now ranking among the top four in China by market share. This latest funding round, supported by state-backed and industrial investors, will fuel the company's strategy to promote sustainable, natural ingredients for the industry.

According to PharmCube's MedAlpha® database, Series C rounds display stable activity in China this year compared to 2024, contrary to the downward trend observed overseas. Click here to request a free trial for NextBiopharm®.